In this paper, we describe the development and evaluation of new cathepsin activatable agents and their comparison to the new αvβ3 integrin targeted agent in the detection of atherosclerosis associated inflammation in apoE−/− mice using established FMT technology. This evidence concerns the gene CTSS and atherosclerosis.